SynthesisFrontiers in pharmacology2025
Mesenchymal stem cell-derived small extracellular vesicles (sEVs) as a therapy for sepsis-related liver injury: evidence from a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-induced liver injury (SILI) is critical in the progression of high morbidity and mortality associated with sepsis which ends in hepatic dysfunction and multi-organ failure. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) are valued for their anti-inflammatory and regenerative potential as favorable strategy. The present systematic review and meta-analysis aimed to assess the effect of MSC- sEVs in rodent models with SILI. Methods: A comprehensive systematic search was carried out in the PubMed, Web of Science, Embase, Scopus, and the Cochrane Library through April 2025. All published studies in relation to the effect of MSC- sEVs in rodent models were included. Pooled standardized mean differences (SMDs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for study outcomes. Results: Ten studies were included in the present study. MSC- sEVs significantly reduced ALT (SMD = -2.49, 95% CI: 3.37, -1.62), AST (SMD = -1.97, 95% CI: 3.32, -0.62), reduced pro-inflammatory cytokines (TNF-α: SMD = -5.23, 95% CI: 7.05, -3.41; IL-6: SMD = -5.00, 95% CI: 7.36, -2.64), and increased survival (OR = 6.11, 95% CI: 2.20-16.98; P = 0.001). No significant effects were observed for IL-10 (SMD = -3.39, 95% CI: 9.47, 2.69) or NLR (SMD = -0.65, 95% CI: 1.75, 0.45). Subgroup analyses illustrated that overall efficacy of treatment may vary dependent to source of sEVs, route of administration, and induction methods. Conclusion: MSC- sEVs is able to improve liver function, inflammation, and survival rate in rodent sepsis model. These findings suggest that MSC- sEVs could be considered as therapeutic strategy for sepsis. These findings not only quantify the effect size of MSC- sEVs but also provide methodological insights for preclinical studies and guide future translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.